8-K/AAccepted Sep 28, 1:18 PM ET
Exascale Labs Files 8-K Amendment Adding Financials for BCAR Acquisition
Accepted (ET)
1:18 PM
Sep 28, 2026
Filed
Sep 28, 2026
Documents
15
Size
1.3 MB
Summary
Exascale Labs Files 8-K Amendment Adding Financials for BCAR Acquisition
What Happened
Exascale Labs Holdings Inc. filed an amendment to its original Form 8-K (filed Sept. 2, 2026) on Sept. 28, 2026 to supply material financial information related to Exascale and BCAR in connection with the recently disclosed transaction. The amendment provides audited consolidated financial statements and MD&A for Exascale for the years ended June 30, 2026 and 2025; unaudited interim financial statements and MD&A for BCAR for the three- and six-month periods ended June 30, 2026 and for the period from BCAR’s March 20, 2025 inception through June 30, 2025; and unaudited pro forma condensed combined financial information of BCAR and Exascale as of June 30, 2026 and for the year ended June 30, 2026. The amendment also discloses a change in the registrant’s certifying accountant (Item 4.01).
Key Details
- Adds audited consolidated financial statements and MD&A for Exascale for years ended June 30, 2026 and 2025.
- Adds BCAR’s unaudited interim consolidated financial statements and MD&A for the three- and six-month periods ended June 30, 2026 and for March 20, 2025 (inception) through June 30, 2025.
- Includes unaudited pro forma condensed combined financial information for BCAR and Exascale as of June 30, 2026 and for the year ended June 30, 2026.
- Reports a change in Exascale’s certifying accountant (Item 4.01); the amendment does not otherwise modify the original 8‑K.
Why It Matters
These added audited, interim and pro forma financials provide investors with the detailed historical results and combined financial view needed to assess the financial impact of the BCAR transaction and Exascale’s recent performance. The change in certifying accountant is also material because it relates to who reviews and attests to Exascale’s financial statements. Investors should review the newly filed financial statements and MD&A to evaluate revenue, profitability, cash position, and any pro forma adjustments tied to the acquisition. The original Form 8-K remains in effect except for the items amended by this filing.